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Introduction: Although plasma lipid levels are known to inﬂuence the risk of cardiovascular disease
(CVD), little is known about their effect on atherosclerotic plaque composition. To date, large-scale
genome-wide association studies have identiﬁed 157 common single-nucleotide polymorphisms
(SNPs) that inﬂuence plasma lipid levels, providing a powerful tool to investigate the effect of plasma
lipid levels on atherosclerotic plaque composition.
Methods: In this study, we included 1443 carotid endarterectomy patients from the Athero-Express
Biobank Study with genotype data. Plasma concentrations of high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglycerides (TG) were
determined at the time of endarterectomy. Atherosclerotic plaques, obtained during surgery, were his-
tologically examined. For all patients, we calculated weighted genetic burden scores (GBS) for all lipid
traits on the basis of the available genotype data. Plasma lipid levels and GBS were tested for association
with 7 histological features using linear and logistic regression models.
Results: All GBS were associated with their respective plasma lipid concentrations (pHDL-C ¼ 2.4  1014,
pLDL-C ¼ 0.003, pTC ¼ 2.1  106, pTG ¼ 3.4  108). Neither the measured plasma lipids, nor the GBS,
were associated with histological features of atherosclerotic plaque composition. In addition, neither the
plasma lipids nor the GBS were associated with clinical endpoints within 3 years of follow-up, with the
notable exception of a negative association between HDL-C and composite cardiovascular endpoints.
Conclusion: This study found no evidence that plasma lipid levels or their genetic determinants inﬂuence
carotid plaque composition.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
There is a wealth of evidence that plasma lipid levels inﬂuence
the risk of cardiovascular disease (CVD). Most notably, Mendelianntal Cardiology, University
02.523, PO Box 85500, 3508
Pasterkamp).
rved.randomization studies have contributed unambiguous support for
a causal effect of LDL-C and TG on CVD, while the evidence for the
causality of HDL-C is perhaps not as clear [1e6]. Yet, for all the
accumulated evidence on plasma lipids, the biological mechanisms
by which they increase CVD risk are still incompletely understood.
The traditional paradigm of atherosclerosis has been the accumu-
lation of plasma lipids in the vascular wall contributing to the
formation of an unstable plaque, the rupture of which causes a
cardiovascular event. Much research has been performed in animal
models and in vitro studies, but little is known about changes to
M.A. Siemelink et al. / Atherosclerosis 242 (2015) 351e356352human atherosclerotic plaque composition due to changed plasma
lipid concentrations.
In addition to known determinants of plasma lipid levels such as
diet, metabolism and bodyweight, it is clear that there is a heritable
polygenic basis for inter-individual variation in lipid levels [7]. A
large meta-analysis of genome-wide association studies by the
Global Lipids Genetics Consortium (GLGC) identiﬁed 157 common
single-nucleotide polymorphisms (SNPs) associated with high-
density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), total cholesterol (TC) and triglycerides (TG)
blood concentrations [8]. Although the individual effects of these
SNPs on plasma lipid concentrations are modest, the cumulative
impact of multiple variants may be substantial. Since these SNPs
confer a lifelong effect, they provide a useful tool to investigate the
possible effects of plasma lipid levels on atherosclerotic plaque
composition.
The AtheroeExpress Biobank Study (AE) has enrolled patients
who underwent carotid endarterectomy (CEA) followed by exten-
sive histological analysis of carotid plaque characteristics, geno-
typing and a 3 year follow-up for clinical endpoints. We
investigated the association of plasma lipid concentrations with 7
features of atherosclerotic plaque composition in the Athero-
Express. Subsequently, we performed similar associations using
weighted genetic burden scores (GBS) to assess the cumulative
effect of the known 157 lipid associated SNPs on plaque composi-
tion. In addition, we investigated if plasma lipids, or their genetic
determinants, were associated with clinical endpoints during
follow-up.
2. Methods
2.1. Inclusion
The Athero-Express Biobank Study is an ongoing multi-center
cohort study including patients that underwent carotid endarter-
ectomy and was previously described in more detail [9,10]. In short,
blood and atherosclerotic plaques were obtained during surgery
and stored at 80 C. Clinical data were obtained through stan-
dardized questionnaires, pre-operative admission charts and pa-
tient medical ﬁles. Medical ethics committees of both hospitals
approved the study and all patients included in the study provided
informed consent.
2.2. Plaque histology
Atherosclerotic plaque specimens were collected during carotid
endarterectomy, processed and analyzed according to a standard-
ized and previously reported protocol [9]. In short, the specimen
was parafﬁn-embedded, the culprit lesion was identiﬁed and a 5
micron cross-section was sliced, stained and quantiﬁed by micro-
scopy. Hematoxylin and eosin (H&E) staining was used for assess-
ment of calciﬁcations and atheroma. Staining with Elastin von
Gieson (EVG) was used for plaque hemorrhage and Picrosirius Red
for assessment of collagen. Immunohistochemical staining was
performed for assessment of macrophages (anti-CD68), micro-
vessels (anti-CD34) and smooth-muscle cells (anti-alpha smooth
muscle actin). The presence of calciﬁcations and collagen were
classiﬁed as scarce/absent or high. Atheroma was classiﬁed as
below of above 10% of the plaque area. Plaque hemorrhage was
classiﬁed as present or absent. Plaque microvessels were quantiﬁed
by number of individual vessels per microscopy ﬁeld. Plaque
smooth-muscle cells and macrophages were quantiﬁed as per-
centage of the microscopy ﬁeld area. For quantitative measures,
multiple random microscopy ﬁelds were digitized, quantiﬁed and
averaged.2.3. Laboratory measurements
If routine clinical plasma lipids measurements were performed
prior to surgery, that data was used. If available, stored pre-
operative plasma samples were used for additional plasma lipids
measurements at the clinical chemistry laboratory of the University
Medical Center Utrecht. If both routine and additional lipids values
were available the values were averaged (correlations routine vs.
additional measurements: Spearman's r > 0.94 for all lipid traits).
2.4. SNP genotyping and imputation
Details on genotyping, quality control and imputation have been
published previously [11]. In brief, DNA was extracted from whole
blood, or alternatively fromplaque samples, following standardized
in-house validated protocols. Genotyping was done using
commercially available genotyping chips. The ﬁrst batch (Athero-
Express Genomics Study 1, AEGS1) was genotyped using Affymetrix
Genome-Wide Human SNP Array 5.0, the second batch (Athero-
Express Genomics Study 2, AEGS2) was genotyped using the Affy-
metrix Axiom® GW CEU 1 Array (Affymetrix, Santa Clara, CA, USA).
We adhered to community standard quality control and assurance
(QCA) procedures to clean the genotype data obtained in AEGS1
(N ¼ 571) and AEGS2 (N ¼ 868) [12]. We used the 998 phased
haplotypes from the Genome of the Netherlands Project release 4
(GoNL4) encompassing 19,763,454 SNPs as the reference panel for
imputation [13].
2.5. Weighted genetic burden scores
The Global Lipids Genetics Consortium identiﬁed 157 loci
associated with circulating lipid levels, and reported their effect
sizes on plasma lipids (included in online supplement). We calcu-
lated weighted genetic burden scores using the risk alleles from
these SNPs and their respective effect sizes. To account for the
imputation quality we used the risk allele dosages to construct the
GBS. The following formula was used to calculate the GBS for each
lipid [14e16].
GBSlipid ¼ Sðbn*DnÞ
where an individual's GBSlipid is the sum of the effect size (b) of the
risk allele of the nth SNP multiplied by the individual's dosage (D)
of the risk allele for the nth SNP.
2.6. Follow-up and clinical outcome
Clinical follow-up was performed by contacting patients to ﬁll-
in standardized questionnaires at 1, 2 and 3 years after surgery. In
case no response to the questionnaire was received the general
practitioner was contacted for information. All events were
assessed by two members of an outcome assessment committee.
Cardiovascular death (CV-death) was deﬁned as death of presumed
vascular origin (stroke, myocardial infarction, sudden death, other
vascular causes). Composite (cardiovascular) endpoints were
deﬁned as the occurrence of any cardiovascular event including CV-
death, non-fatal stroke or myocardial infarction, or any vascular
intervention not planned at the time of inclusion. Restenosis was
determined based on routine clinical assessment of ipsilateral ca-
rotid artery stenosis using duplex echocardiography at 1 year post
carotid endarterectomy.
2.7. Statistics
Statistical analysis was performed in RStudio using R (v3.1.2).
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for continuous traits and a logistic model for categorical traits
correcting for age, sex, hospital of surgery, diabetes or statin use, a
dummy-variable representing the genotyping batch (AEGS1 or
AEGS2), and the ﬁrst 10 principal components. Prior to analysis,
outliers at more than three standard deviations were removed from
the data and traits that were not normally distributed (smooth-
muscle cells, macrophages, microvessels) were normalized using
Box-Cox transformation. We used PLINK [17] (version 1.7) to
determine the associations of individual SNPs.
3. Results
3.1. Cohort characteristics
Clinical cohort characteristics are summarized in Table 1. The
Athero-Express cohort is comprised of patients with advanced
stages of atherosclerosis, as is evident from a high prevalence of
atherosclerotic disease in various vascular territories (cerebrovas-
cular accident 82.3%, coronary artery disease 29.9%, peripheral ar-
tery occlusive disease 20.7%). Associations of individual plasma
lipids and GBSwith risk factors are shown in Supplemental Tables 1
and 2
3.2. GBS associate with circulating lipids
To ascertain the validity of the calculated GBS as a means to
investigate the relationship between plasma lipids and CVD, weTable 1
Cohort characteristics.
Characteristic Median (IQR) Missing (%)
Age, years 69.9 (62.0e76.0) 0.0
SBP, mmHg 153 (138e170) 16.6
DBP, mmHg 80 (74e90) 16.6
BMI, kg/m [2] 25.9 (24.0e28.4) 6.9
GFR, ml/min/1.73 m [2] 72.2 (58.9e85.1) 3.5
hsCRP, mg/l 1.97 (0.92e4.41) 38.9
HDL-C, mmol/l 1.11 (0.90e1.37) 36.2
LDL-C, mmol/l 2.70 (2.02e3.39) 39.7
TC, mmol/l 4.63 (3.83e5.46) 33.3
TG, mmol/l 1.39 (1.00e1.96) 36.5
Smooth-muscle cells,#/ﬁeld 1.34 (0.50e2.78) 2.9
Macrophages,#/ﬁeld 0.34 (0.08e1.047) 4.2
Microvessels,#/ﬁeld 7.0 (4.0e11.3) 10.1
Percentage Missing (%)
Gender, male 67.8 0.0
Smoking 24.3 2.3
Statin 76.3 0.1
Antiplatelets 88.7 0.3
Diabetes 23.0 0.0
Hypertension 85.6 0.1
CAD 29.9 0.1
MI 19.3 1.1
Stroke 33.1 0.0
CVA 82.3 0.0
PAOD 20.7 0.1
Calciﬁcation, high 50.2 1.9
Collagen, high 80.3 1.8
Atheroma, >10% 72.5 1.7
Plaque hemorrhage, present 60.4 1.8
Clinical characteristics of all patients at the time of study inclusion. Patient history of
CAD, MI, Stroke, CVA and PAOD were scored as percentage of cases prior to inclu-
sion. hsCRP, smooth-muscle cells, macrophages and microvessels are presented as
non-transformed data. IQR, interquartile range; SBP, systolic blood pressure; DBP,
diastolic blood pressure; BMI, body-mass index; eGFR, estimated glomerular
ﬁltration rate (MDRD formula); hsCRP, high-sensitive C-reactive protein; CAD,
coronary artery disease; MI, myocardial infarction; CVA, cerebrovascular accident;
PAOD, peripheral artery occlusive disease.ﬁrst conﬁrmed the relationship between GBS andmeasured plasma
lipids. All the GBS showed signiﬁcant associations with their
respective plasma lipid concentrations (pHDL-C ¼ 2.4  1014, pLDL-
C ¼ 0.003, pTC ¼ 2.1  106, pTG ¼ 3.4  108) and corrected plasma
lipids showed an increasing trendwith higher GBS for all lipid traits
(Fig. 1AeD). This replicates previous studies, and conﬁrms the ef-
fects of these SNPs on plasma lipids in this cohort of patients with
severe atherosclerotic disease. Remarkably, there was only a
moderate association between the LDL burden score and measured
LDL-C levels, which may be explained by statin-induced favorable
LDL-C levels, irrespective of the genetic burden (Suppl. Fig. 1).
Additionally, we investigated all SNPs individually for their asso-
ciation with each of the plasma lipids (Supplemental Table 3), yet
none of the SNPs were signiﬁcant after Bonferroni correction.
3.3. Associations with plaque characteristics
We proceeded to investigate if measured plasma lipid levels
were associated with histological features of atherosclerotic plaque
composition. Plaque features were determined quantitatively
(number of smooth-muscle cells, macrophages, and microvessels)
or semi-quantitatively (for crude levels of collagen, calciﬁcation,
plaque hemorrhage, and atheroma), and associated with lipid
levels. We observed nominally signiﬁcant associations for HDL-C
with fewer plaque macrophages (p ¼ 1.6  103) as well as for
LDL-C (p ¼ 2.0  102), TC (p ¼ 8.2  103) and TG (p ¼ 1.4  102)
with less plaque calciﬁcation (Table 2). Similarly, we investigated if
GBS of lipids were associated with histological features of athero-
sclerotic plaque composition. Nominally signiﬁcant associations
were observed for both LDL-scores (p ¼ 2.6  102) and TC-scores
(p ¼ 2.0  102) with atheroma size (Table 2). After Bonferroni
correction however, none of the plasma lipids and none of the GBS
were signiﬁcantly associated with histological plaque features.
Since the use of statins was high in this cohort (76.3%) and strongly
associated with plasma LDL-C (p ¼ 8.9  1020) and plasma TC
concentrations (p ¼ 2.8  1015) (Supplemental Table 1), we also
performed a subgroup analysis in the 344 patients not using statins
(Supplemental Table 4). This showed generally similar results, with
the exception of stronger negative associations with plaque calci-
ﬁcation for the LDL-burden scores (p ¼ 6.5  103) and TC-burden
scores (p ¼ 7.6  103), although these were not signiﬁcant after
Bonferroni correction. Additionally, we investigated all SNPs indi-
vidually for their association with plaque characteristics, but none
reached statistical signiﬁcance after Bonferroni correction
(Supplemental Table 3).
3.4. Associations with clinical endpoints
Despite the lack of signiﬁcant associations with plaque features,
we investigated whether plasma lipids and their corresponding
GBS were associated with the incidence of cardiovascular end-
points within 3-years of follow-up. Increased HDL-C levels were
signiﬁcantly associated with a reduction of composite cardiovas-
cular endpoints, also after correction for multiple testing, whereas
none of the GBS were signiﬁcantly associated (Table 3). In addition,
we found no signiﬁcant associations between individual SNPs and
clinical endpoints, after correction for multiple testing
(Supplemental Table 3).
4. Discussion
To our knowledge, this study is the ﬁrst effort to associate
plasma lipids and genetic factors inﬂuencing them, with histolog-
ical features of carotid plaques, which are widely considered to be
surrogates of cardiovascular disease severity and risk [10,18,19]. We
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Fig. 1. Relationships between plasma lipids and corresponding genetic burden scores. Combined histograms-boxplots showing the model relationship between genetic burden
scores and plasma lipids using linear regression modeling. Histograms show distribution (left axis) of the genetic burden score (x axis) in the cohort population. Boxplots show
corrected plasma lipid concentrations (right axis), i.e. model ﬁtted values, within the respective histogram bin. Signiﬁcance of the (continues) association between genetic burden
score and the respective plasma lipid denoted as p-value. A) HDL-C; B) LDL-C; C) Total TC; D) TG.
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plasma lipids are associated with carotid atherosclerotic plaque
composition. This may seem somewhat surprising in light of the
current paradigm of the “vulnerable plaque”. Given the over-
whelming evidence of LDL-C as a causal contributor to CVD risk, it is
perhaps remarkable that no effects on plaque composition were
found.
Several points are worth highlighting and may explain the lack
of association of plasma lipids or the GBS with plaque features. (i)
We performed this study in a patient cohort of limited size, which
lacked well-matched healthy subjects as controls as it is unfeasible
to obtain carotid plaque samples from healthy subjects. This may
have limited biological variance in the observed plaque features.
Both cohort size and lack of controls may limit the power to
conﬁdently prove a lack of associations, particularly if the magni-
tude of effect is small. (ii) The patients in this cohort had severe
atherosclerotic disease and many of them suffered from comor-
bidities with effects we may not have been able to fully account for
in the analysis. (iii) The majority of patients received lipid altering
medications, which may have variable effects on individual lipid
level improvement. This is something we cannot correct for in the
model, and may explain the relatively weak association of the LDL-
burden score with the measured LDL plasma concentrations inthese patients, especially when compared to the other lipid frac-
tions. The high use of lipid-lowering medications may also have
improved plaque composition, and may have prevented cardio-
vascular events in some patients. This could mask the effects of
lipids or the GBS, although sub-analysis in non-statin users showed
generally similar results. (iv) We have shown that carotid plaque
histological examination is prone to some inter-observer bias [20].
This is due to a certain level of subjective interpretation by the
observer, affecting the precision to determine plaque composition.
(v)With regard to plasma lipids, wewere only able to include a pre-
operative measurement, while plasma lipid concentrations may
vary considerably over time. (vi) Also, we suffered from the
incomplete availability of plasma lipid concentrations (missingness
33.3%e39.7%), which may contribute to bias. (vii) For most SNPs
previously associated with lipid levels, the mechanism of action is
unknown. Conceivably, unknown factorsmaymodify their effect on
plasma lipids between individuals. This would also explain the
different effect sizes when comparing our study to the GLGC study
results.
An alternative explanation is that plasma lipid levels may have a
negligible effect on carotid plaque composition, andmay exert their
effects on the risk of CVD through other mechanisms (for example,
coronary calciﬁcation [21]). In accordance, a recent meta-analysis
Table 3
Associations of plasma lipids and their genetic burden scores with clinical endpoints.
HDL-C LDL-C TC TG
HR (95% CI) p val HR (95% CI) p val HR (95% CI) p val HR (95% CI) p val
Restenosisa 1.23 (1.02e1.48) 7.0  102 1.15 (0.93e1.41) 0.28 1.25 (1.04e1.52) 5.0  102 0.92 (0.76e1.1) 0.46
Stroke 0.87 (0.67e1.14) 0.31 0.82 (0.62e1.09) 0.17 0.74 (0.57e0.97) 2.9  102 1.01 (0.79e1.29) 0.95
Myocardial Infarction 0.75 (0.52e1.1) 0.14 1.08 (0.74e1.57) 0.68 1.11 (0.78e1.58) 0.55 1.12 (0.82e1.54) 0.46
Cardiovascular death 0.77 (0.53e1.1) 0.15 0.81 (0.54e1.19) 0.28 0.71 (0.49e1.01) 5.7  102 1.18 (0.89e1.58) 0.25
Composite endpoints 0.74 (0.63e0.86) 1.1  104 0.86 (0.74e1.01) 6.0  102 0.86 (0.75e0.99) 3.6  102 1.12 (0.99e1.27) 7.9  102
HDL-score LDL-score TC-score TG-score
HR (95% CI) p val HR (95% CI) p val HR (95% CI) p val HR (95% CI) p val
Restenosisa 1.02 (0.88e1.19) 0.81 1.05 (0.89e1.23) 0.63 1.04 (0.89e1.22) 0.66 0.99 (0.85e1.16) 0.94
Stroke 0.91 (0.74e1.12) 0.37 1.15 (0.94e1.41) 0.19 1.07 (0.87e1.31) 0.53 1.05 (0.86e1.29) 0.62
Myocardial Infarction 0.85 (0.65e1.11) 0.23 0.91 (0.69e1.2) 0.52 0.88 (0.67e1.15) 0.35 1.04 (0.8e1.36) 0.76
Cardiovascular death 0.91 (0.71e1.17) 0.46 0.97 (0.75e1.26) 0.80 0.93 (0.71e1.2) 0.56 1.18 (0.92e1.52) 0.18
Composite endpoints 0.94 (0.84e1.05) 0.27 1.03 (0.92e1.15) 0.61 0.98 (0.88e1.09) 0.74 0.98 (0.88e1.09) 0.72
Cox proportional hazard model associating plasma lipids and genetic burden scores with clinical endpoints within 3 years. Results are given as hazard ratio per standard
deviation increase with 95% conﬁdence intervals.
a Restenosis was assessed after 1 year by carotid echography as more than 50% stenosis of the vascular lumen, and was associated using logistic regression modeling,
showing odds ratio (95% CI) instead of hazard ratio.
Table 2
Associations of Plasma lipids and their genetic burden scores with plaque composition.
Lipid spectra HDL-C LDL-C TC TG
Beta (SE) P Beta (SE) P Beta (SE) P Beta (SE) P
Smooth-muscle cells 0.21 (0.13) 0.097 0.06 (0.05) 0.206 0.00 (0.04) 0.966 0.02 (0.06) 0.678
Macrophages 0.39 (0.12) 0.002 0.03 (0.05) 0.598 0.03 (0.04) 0.371 0.02 (0.06) 0.726
Microvessels 0.04 (0.21) 0.843 0.09 (0.08) 0.278 0.03 (0.06) 0.666 0.18 (0.09) 0.052
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Calciﬁcation 1.08 (0.79e1.49) 0.678 0.84 (0.74e0.95) 0.020 0.85 (0.77e0.94) 0.008 0.81 (0.7e0.93) 0.014
Collagen 1.26 (0.84e1.89) 0.351 1.15 (0.98e1.34) 0.144 1.05 (0.94e1.19) 0.470 0.99 (0.83e1.19) 0.942
Atheroma 0.74 (0.52e1.06) 0.171 1.14 (0.99e1.32) 0.127 1.11 (0.99e1.24) 0.135 1.09 (0.93e1.3) 0.383
Plaque hemorrhage 0.89 (0.64e1.24) 0.553 1.00 (0.88e1.14) 0.996 1.03 (0.93e1.13) 0.687 1.10 (0.95e1.28) 0.298
Genetic Burden Scores HDL-score LDL-score TC-score TG-score
Beta (SE) P Beta (SE) P Beta (SE) P Beta (SE) P
Smooth-muscle cells 0.12 (0.13) 0.366 0.08 (0.13) 0.536 0.04 (0.13) 0.728 0.06 (0.16) 0.728
Macrophages 0.06 (0.13) 0.667 0.18 (0.13) 0.174 0.08 (0.13) 0.530 0.15 (0.16) 0.334
Microvessels 0.15 (0.22) 0.496 0.02 (0.22) 0.919 0.02 (0.22) 0.939 0.53 (0.27) 0.055
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Calciﬁcation 0.82 (0.58e1.15) 0.324 0.83 (0.6e1.16) 0.365 0.80 (0.57e1.11) 0.254 0.77 (0.51e1.16) 0.294
Collagen 0.84 (0.55e1.28) 0.503 1.47 (0.97e2.23) 0.125 1.35 (0.9e2.02) 0.228 1.52 (0.91e2.55) 0.183
Atheroma 0.94 (0.64e1.38) 0.799 1.67 (1.15e2.44) 0.026 1.69 (1.17e2.45) 0.020 1.49 (0.94e2.39) 0.159
Plaque hemorrhage 0.85 (0.6e1.21) 0.446 1.18 (0.84e1.67) 0.421 1.21 (0.86e1.7) 0.348 1.15 (0.75e1.78) 0.589
The association of plasma lipids and genetic burden scores with histological features of plaque composition. Smooth-muscle cells, macrophages and microvessels were scored
quantitatively as the number of features per microscopy ﬁeld. Quantitative histology features were normalized using Box-Cox transformation and associated to plasma lipids
and GBS using linear regression modeling. Calciﬁcation, collagen, atheroma and plaque hemorrhage were determined semi-quantitatively. Plasma lipids and burden scores
were associated to increased abundance of the semi-quantitative feature using logistic regression modeling. Results are given as model beta with standard error, or as odds
ratios with 95% conﬁdence interval.
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through improvement of inﬂammation, not lipid levels [22].
We also investigated if plasma lipids or genetic variants were
associatedwith clinical endpoints within 3 years, but failed to show
an association. We also included myocardial infarction as an
endpoint, as there is a partially shared etiology [23] and patients
with carotid artery disease are at increased risk of cardiovascular
disease in other vascular territories [24]. The notable exception is a
negative association between HDL-C levels and the occurrence of
composite cardiovascular endpoints, which may represent a non-
causal effect (e.g. due to reverse causation or uncorrected con-
founding), consistent with recent Mendelian randomization
studies [2,4,5]. The aforementioned limitations as well as the
limited follow-up period of 3 years in this actively monitored and
treated patient groupmay have decreased power to show an effect.
Replication at present seems challenging, as we are unaware of
cohorts that possess similar data with adequate sample size. Futureefforts in larger samples will have better power to address the
causal role of lipid fractions and the “vulnerable plaque” in car-
diovascular disease. If it is true that there is no relation between
lipid fractions and plaque features, then that would genuinely
question themechanisms bywhich plasma lipids contribute to CVD
risk, as well as the paradigm of the vulnerable plaque, yet we do not
believe our current results are sufﬁciently robust to arrive at that
conclusion.
In summary, this study found no evidence that plasma lipid
levels or genetic determinants of plasma lipid levels inﬂuence ca-
rotid plaque composition.
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